We stand at the threshold of a new era for pharmaceutical supply chains, driven by breakthroughs in personalised medicine, the rising prevalence of biologics, and the integration of digital
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh